Wednesday, May 13, 2026, San Antonio, Texas, 11:15 AM – 12:45 PM Central Time (12:15 PM – 1:45 PM Eastern Time)

Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Strategies to Safely and Effectively Implement Antibody-Drug Conjugates

A Complimentary NCPD Symposium Held During the 51st Annual ONS Congress

 

 

 

Register for in-person Register for webcast

Program Schedule — Central Time
10:45 AM – 11:15 AM — Registration and Lunch
11:15 AM – 12:45 PM — Educational Meeting

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)
 
 
Faculty
Courtney Arn, CNP
The James Cancer Hospital and Solove Research Institute
The Ohio State University
Columbus, Ohio

Jamie Carroll, APRN, MSN, CNP
Assistant Professor, Oncology
Mayo Clinic
Rochester, Minnesota

Edward B Garon, MD, MS
Professor
Director, Thoracic Oncology Program
Director, Signal Transduction and Therapeutics Research Program
David Geffen School of Medicine at UCLA
Jonsson Comprehensive Cancer Center
Los Angeles, California

Heather McArthur, MD, MPH, FASCO
Professor, Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas
Moderator
Kathleen N Moore, MD, MS
Deputy Director and Director, Phase 1 Clinical Trials
Fred and Pamela Buffett Cancer Center at the University of Nebraska
Omaha, Nebraska



Meeting space has been assigned to provide a symposium supported by AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Merck during the Oncology Nursing Society’s (ONS) 51st Annual Congress, May 13-17, 2026 in San Antonio, TX. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Central Time
10:45 AM – 11:15 AM — Registration and Lunch
11:15 AM – 12:45 PM — Educational Meeting

Topics to Be Discussed

  • Rationale for the Use of Antibody-Drug Conjugates (ADCs) as Cancer Treatment
  • Current and Future Role of ADCs in Cancer Therapy
  • Practical Considerations with ADCs
  • Cytopenias Associated with ADCs
  • Gastrointestinal Adverse Events (AEs) Documented with ADCs
  • Recognition and Management of Interstitial Lung Disease/Pneumonitis with ADCs
  • Potential for Mucositis/Stomatitis with ADCs
  • Ocular Toxicities with ADCs
  • Cardiovascular AEs Associated with Select ADCs
  • Other Toxicities Reported with 1 or More ADCs

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Consider the scientific justification for antibody-drug conjugates (ADCs) as a therapeutic approach for patients with various tumor types, and recall the differential targets, structural components and mechanisms of activity of different clinically available and investigational ADCs.
  • Appraise available clinical research data with novel ADCs for various cancers, and consider the current and potential role of these approaches in routine clinical care.
  • Appreciate the pathophysiology and severity of common and rare toxicities associated with ADCs employed in the treatment of different tumor types.
  • Understand the incidence of toxicities observed in pivotal trials evaluating novel ADCs demonstrating efficacy in the management of various tumor types, and educate patients about to commence therapy with these approaches regarding the potential development of adverse events and what to do if they are suspected.
  • Recall strategies commonly employed to identify, manage and mitigate toxicities resulting from anticancer treatment with ADCs, and use this information to appropriately intervene for patients in whom these side effects are suspected or diagnosed.
  • Understand the role of multidisciplinary specialists such as cardiologists, ophthalmologists and other medical professionals in the diagnosis and management of various ADC-associated toxicities, and effectively educate patients regarding the potential need for and importance of specialty referral.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This program will be submitted for ONCC/ILNA certification.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Ms Carroll — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Lilly, Novartis. Dr McArthur — Advisory Committees: Arvinas, AstraZeneca Pharmaceuticals LP, Boston Scientific Corporation, Celcuity, Daiichi Sankyo Inc, Delcath Systems Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc; Consulting Agreements: ALX Oncology. Dr Moore — Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, GSK, Mersana Therapeutics Inc; Consulting Agreements: Aadi Bioscience, AbbVie Inc, AstraZeneca Pharmaceuticals LP, BioNTech SE, Caris Life Sciences, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Duality Biologics, GSK, ImmunoGen Inc, Janssen Biotech Inc, Merck, Regeneron Pharmaceuticals Inc, Schrödinger, Takeda Pharmaceuticals USA Inc, Verastem Inc, Whitehawk Therapeutics, Zentalis Pharmaceuticals, Zymeworks Inc; Contracted Research: Accent Therapeutics, Advaxis Inc, Allarity Therapeutics, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, GSK, Immunocore, Iovance Biotherapeutics, Regeneron Pharmaceuticals Inc, Schrödinger, Verastem Inc; Data and Safety Monitoring Boards/Committees: Bicycle Therapeutics; Nonrelevant Financial Relationships: ASCO, GOG Partners, NRG Oncology. Additional faculty to be announced.

MODERATOR
To be announced.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Merck.

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

 
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.

No registration fee is charged for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.

NOTICE
Registration for this event is independent of registration for the 2026 ONS Congress.

IN-PERSON registration for nurses and healthcare providers

I am a practicing nurse or healthcare provider involved in the care of patients with cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
 
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
WEBCAST registration for all professionals

We will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.